Jason Brooks, MD
Family Medicine · Palmer, AKNPI 1164465712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 30.1% of the total. Reporting peaked in 2022 at $737 and has fallen 52.6% since, to $349 in 2025. Among family medicine clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$376
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$373
- AbbVie$364
- Lilly USA, LLC$246
- Novartis$127
- plus $994 from 23 others
What the payments were for
- Food & beverage$3,546100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $1,067 |
| Novo Nordisk | 16 | $376 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $373 |
| AbbVie(2 entities) | 19 | $364 |
| Lilly USA, LLC | 13 | $246 |
| Novartis | 2 | $127 |
| Pfizer | 6 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Exact Sciences | 4 | $89 |
| GSK | 4 | $80 |
| Merck | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Boehringer Ingelheim | 3 | $57 |
| Amgen | 2 | $55 |
| Biohaven Pharmaceuticals, Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Acadia Pharmaceuticals Inc | 1 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Antares Pharma, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,546 in reported general payments places this provider in the 90th percentile of 334 family medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 14 | $26,090 |
| FarxigaDapagliflozin Propanediol | 16 | $25,650 |
| OzempicSemaglutide | 14 | $25,457 |
| MounjaroTirzepatide | 11 | $22,746 |
| EliquisApixaban | 11 | $17,904 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,522 |
| Levothyroxine Sodium | 12 | $1,823 |
| Rosuvastatin Calcium | 89 | $1,764 |
| Nebivolol Hcl | 13 | $751 |
| Allopurinol | 13 | $728 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $568 |
| Metoprolol Succinate | 35 | $508 |
| Atorvastatin Calcium | 42 | $419 |
| Lisinopril | 39 | $392 |
| Tamsulosin Hcl | 17 | $337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $246 | $48,83625 claims |
| AstraZenecaFarxiga | $1,067 | $25,65016 claims |
| Novo NordiskOzempic | $376 | $25,45714 claims |
| PfizerEliquis | $121 | $17,90411 claims |
| GSKTrelegy Ellipta | $80 | $11,52212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 family medicine providers in Alaska.
Other family medicine in Palmer
- Bryan DahmsPalmer$3K
- Rachel CuevasPalmer$2K
- Robert SkalaEagle River$38K
- John CullenValdez$32K
- Mary FolandAnchorage$15K
- Ilona FarrAnchorage$14K
- Eric MiknichAnchorage$13K
- Ray KelleyWasilla$9K
- Russell PierceFairbanks$7K
- Heather JonesEagle River$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.